Decoding Autoimmunity: The Discoveries Redefining Immunology

ORLANDO, Fla. – November 09, 2026

The pharmaceutical industry often looks to late-stage clinical trials and multibillion-dollar acquisitions to gauge the future of medical markets. But true market disruption—the kind that redefines therapeutic categories and establishes new standards of care—begins much earlier. It starts in the quiet persistence of academic laboratories mapping the cellular machinery of disease.

At the American College of Rheumatology (ACR) Convergence conference in Orlando this week, the broader healthcare sector was reminded of this reality. Two veteran researchers from the Hospital for Special Surgery (HSS), Dr. Mary K. Crow and Dr. Jane E. Salmon, were honored for decades of work that fundamentally altered the commercial and clinical landscape of systemic lupus erythematosus (SLE) and autoimmune disease management.

Dr. Crow received the Evelyn V. Hess Award from the Lupus Foundation of America, while Dr. Salmon was awarded the ACR Distinguished Basic/Translational Researcher Award. Beyond the plaques and peer recognition, their combined body of work serves as a masterclass in how dissecting the "why" behind complex diseases ultimately dictates the "what" of future billion-dollar drug pipelines.

From Bench to Biologic: The Forty-Year Race to Map Autoimmunity

For decades, systemic lupus erythematosus was a therapeutic graveyard. Before 2011, only one FDA-approved therapy had been introduced in sixty years. The standard of care relied heavily on broad-spectrum immunosuppressants and corticosteroids, which often caused as much collateral damage to the patient as the disease itself.

Dr. Mary K. Crow, physician-in-chief emeritus at HSS, spent her forty-year career dismantling this paradigm. By focusing on the fundamental cellular and molecular mechanisms of SLE, she identified the specific biological targets that would eventually become the foundation of today's most lucrative and effective lupus therapies.

"I study lupus in human patients to understand the entire disease process, beginning with how it starts, why the immune system goes awry, the mechanisms of the resulting tissue damage, and how we may intervene," said Dr. Crow during the conference. "My ultimate goal is to better understand lupus so we can identify novel therapies to thwart this disease."

Among her most critical discoveries was mapping the type I interferon pathway. In the early 2000s, Dr. Crow's laboratory was among the first to define the link between interferon overproduction and lupus pathogenesis. This foundational research directly paved the way for AstraZeneca's Saphnelo (anifrolumab), a monoclonal antibody that blocks the type I interferon receptor. Approved in 2021, and recently expanded in April 2026 with a subcutaneous autoinjector formulation, Saphnelo represented the first new therapy for SLE in over a decade that directly targeted this pathway.

Dr. Crow also identified the CD40 ligand as a vital target for T cell-driven autoimmune diseases. This discovery telegraphed another major market maneuver: the development of dapirolizumab pegol by UCB and Biogen. Engineered to inhibit CD40L signaling without triggering the thromboembolic events that plagued earlier iterations, the drug recently met its primary endpoints in the Phase 3 PHOENYCS GO study.

"Over the past 20 years we have learned a tremendous amount about how the immune system is contributing to lupus, which has led to new ideas about therapies, many of which are already in clinical development programs," Dr. Crow noted, pointing toward the next frontier of cellular therapies that re-engineer a patient's own immune cells.

Rewriting the Rules of Pregnancy in Lupus

If Dr. Crow's work redefined the pharmaceutical pipeline, Dr. Jane E. Salmon's research revolutionized the clinical application of those discoveries, particularly in reproductive rheumatology. For generations, women with lupus and antiphospholipid syndrome (APS) were bluntly advised against pregnancy due to severe risks of fetal loss and maternal complications.

Dr. Salmon dismantled this medical dogma. Through her leadership of the PROMISSE study—an 11-year, NIH-funded prospective longitudinal study of 700 pregnant patients—she established that inflammation, not thrombosis, was the primary driver of placental damage and fetal loss in these patients.

This was a seismic shift. It pivoted the standard of care from relying solely on aggressive anticoagulation to incorporating targeted anti-inflammatory strategies. Today, thanks to the risk stratification models developed from her research, over 80 percent of pregnancies in women with lupus and APS result in live births when properly managed.

"This award is a culmination of my life's goal and the recognition by my peers that I have accomplished what I set out to achieve," said Dr. Salmon. "It's magical to go from studying cells to working with pre-clinical models and then to observational and interventional studies. I'm thrilled that I've been able to accomplish what I've wanted to do since I was a student."

Dr. Salmon is not resting on past achievements. She is currently the lead investigator of the IMPACT trial, a groundbreaking study that marks the first time a biologic therapy is being used to prevent serious complications in high-risk pregnancies for women with lupus and APS. By moving biologics into the maternal-fetal medicine space, Dr. Salmon is opening an entirely new frontier for therapeutic intervention.

Her work also confronts the stark demographic realities of autoimmune disease. Lupus disproportionately affects women of color, with African American women diagnosed at rates two to three times higher than Caucasian women. Dr. Salmon was the first to identify an inheritable genetic variation in the Fc-gamma receptor gene as a risk factor for lupus nephritis in African Americans, providing a crucial genetic biomarker for a population historically underserved by broad-brush medical approaches.

Lupus as a Window into Systemic Inflammation

The true market value of the research conducted by Dr. Crow and Dr. Salmon extends far beyond rheumatology clinics. Both researchers have long argued that autoimmune diseases like lupus serve as a concentrated window into systemic inflammation—a biological process at the root of some of the world's most widespread public health crises.

Dr. Salmon demonstrated this by proving that pre-clinical atherosclerosis plaque in the carotid arteries is significantly more prevalent and accelerated in young women with lupus compared to their healthy peers, independent of traditional cardiovascular risk factors.

"What keeps me going in my research is a passion to make a difference in women's health," Dr. Salmon explained. "I also hope to elevate the importance of women's health in our society, because understanding women's diseases helps us understand a broader range of diseases that affect both men and women. I view lupus as a window into the inflammatory-mediated diseases that we see in the general population. If we can understand the inflammatory mechanisms in lupus, we're likely to be able to apply some of those same approaches to diseases such as atherosclerosis in the general public."

This perspective is highly predictive of where pharmaceutical capital is flowing. As major drugmakers look to expand the indications for their blockbuster anti-inflammatory biologics, the mechanisms uncovered in lupus patients are providing the roadmap for next-generation cardiovascular and metabolic therapies.

The Future of the Autoimmune Market

The honors bestowed upon Dr. Crow and Dr. Salmon at the ACR Convergence conference are more than lifetime achievement awards; they are markers of an industry in transition. The autoimmune market is rapidly shifting away from blunt immunosuppressants toward highly targeted, precision-engineered biologics and cellular therapies.

Institutions like the Hospital for Special Surgery—with its deep integration of clinical practice and laboratory research—serve as the ultimate incubators for these paradigm shifts. As biotech investors and pharmaceutical executives map out the next decade of growth, they would do well to look past the late-stage trial announcements and pay closer attention to the foundational immunology being decoded today. The cellular pathways mapped by researchers like Crow and Salmon are not just scientific discoveries; they are the blueprints for the next generation of market dominance.